P-MMUT-101

**P-MMUT-101** is an investigational liver-directed **gene therapy** developed by **Poseida Therapeutics** for **methylmalonic acidemia** caused by defects in the **MMUT** gene. Based on available public pipeline descriptions, it is intended to deliver a functional methylmalonyl-CoA mutase gene to hepatocytes to restore deficient metabolic enzyme activity and reduce the toxic metabolic consequences of MMUT-associated MMA. Publicly available detail on the exact construct, vector, formulation, and clinical stage is limited, but the program has been described as a biologic, liver-directed gene transfer approach for this rare inherited metabolic disorder.